<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02911571</url>
  </required_header>
  <id_info>
    <org_study_id>PROMMIS</org_study_id>
    <nct_id>NCT02911571</nct_id>
  </id_info>
  <brief_title>PRospective Multiple Myeloma Impact Study</brief_title>
  <acronym>PROMMIS</acronym>
  <official_title>Prospective Multicenter Study to Measure the Impact of MMprofiler on Treatment Intention in Active Multiple Myeloma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SkylineDx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medex15</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SkylineDx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment
      intention decisions in active Multiple Myeloma patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective, case-only, study to measure the impact of MMprofiler on treatment
      intention decisions in active MM patients.

      Eligible patients will have their tumor sample analyzed for the prognostic MMprofiler SKY92,
      several cytogenetic markers, gene expression markers, and gene expression clusters.

      A total of 250 patients will be enrolled from up to 7 US centers. Patients will be followed 5
      years after diagnosis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in treatment intention</measure>
    <time_frame>Treatment intention is measured before MMprofiler SKY92 and within 4 weeks after MMprofiler</time_frame>
    <description>Change in treatment intention will be assessed with a physician questionnaire pre- and post MMprofiler assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>3 year Progression Free Survival</measure>
    <time_frame>3 years after diagnosis</time_frame>
    <description>Duration from start of the treatment to disease progression or death (regardless of cause of death), whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3 year Overall Survival</measure>
    <time_frame>3 years after diagnosis</time_frame>
    <description>Duration from start of the treatment to death (regardless of cause of death).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5 year Progression Free Survival</measure>
    <time_frame>5 years after diagnosis</time_frame>
    <description>Duration from start of the treatment to disease progression or death (regardless of cause of death), whichever comes first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5 year Overall Survival</measure>
    <time_frame>5 years after diagnosis</time_frame>
    <description>Duration from start of the treatment to disease progression or death (regardless of cause of death), whichever comes first.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>MMprofiler SKY92</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients will have their bone marrow biopsy sample analyzed for the prognostic MMprofiler SKY92 gene signature</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MMprofiler SKY92 gene signature</intervention_name>
    <description>MMprofiler is a gene expression assay system for detection of the presence (or absence) of the SKY92 &quot;high-risk&quot; gene signature to aid in the determination of the Multiple Myeloma patient's prognosis</description>
    <arm_group_label>MMprofiler SKY92</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Potentially active and active multiple myeloma according to IMWG criteria

          -  Candidates for systemic treatment

        Exclusion Criteria:

          -  ECOG Performance Status &gt; 3

          -  Tumor sample that fails QA or QC criteria for MMprofiler
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saad Usmani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charlotte Mecklenburg Hospital Authority, Carolinas HealthCare System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisette Stork, MSc</last_name>
    <phone>+32479567390</phone>
    <email>lstork@medex15.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Femke de Snoo, MD, PhD</last_name>
    <email>fdesnoo@medex15.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Siegel, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Siegel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Lentzsch, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Saad Usmani, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parameswaran Hari, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2016</study_first_posted>
  <last_update_submitted>April 4, 2018</last_update_submitted>
  <last_update_submitted_qc>April 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

